Literature DB >> 22960495

Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany.

Sandra Dudareva-Vizule1, Judith Koch, Matthias An der Heiden, Doris Oberle, Brigitte Keller-Stanislawski, Ole Wichmann.   

Abstract

In Germany, routine RV-vaccination is not adopted into the national immunization schedule as of 2012. Because RV-vaccines were already on the market since 2006, in 2010 a moderate (58%) and low (22%) vaccine uptake was observed in the 5 eastern federal states (EFS) and the 11 western federal states (WFS), respectively. To assess the impact of RV-vaccination, we compared the incidence rates (IR) of RV-related hospitalizations before (2004‒2006) and in seasons after (2008/09-2010/11) RV-vaccine introduction in Germany by utilizing data from the national mandatory disease reporting system. In the EFS, the IR was significantly reduced in age-groups < 18 mo in 2008/09 and in age-groups < 24 mo in 2009/10-2010/11. In the WFS an IR-reduction was observed only in age-groups < 12 mo in 2008/09 and in age-groups < 18 mo in 2009/10-2010/11. Overall IR-reduction in age-groups < 24 mo comparing 2008-11 with 2004-06 was 36% and 25% in EFS and WFS, respectively. In addition, we computed IR-ratios (IRR) in the seasons after mid-2006 with negative binomial regression. The effect of vaccination was independent from the geographic region. Vaccination was associated with a significant reduction in RV-related hospitalizations in the age-groups 6-23 mo. Most prominently, vaccination of 50% of infants led to an estimated decrease in age group 6-11 mo by 42%. No significant reduction was observed in age-groups ≥ 24 mo. In conclusion, in the German setting with low to moderate vaccine uptake, RV-related hospitalization incidence decreased substantially depending on the achieved vaccination coverage, but only in the first two years of life.

Entities:  

Keywords:  Germany; hospitalization; impact; incidence; nosocomial; rotavirus; vaccination

Mesh:

Substances:

Year:  2012        PMID: 22960495      PMCID: PMC3660760          DOI: 10.4161/hv.21593

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  30 in total

1.  Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.

Authors:  Guillermo M Ruiz-Palacios; Irene Pérez-Schael; F Raúl Velázquez; Hector Abate; Thomas Breuer; SueAnn Costa Clemens; Brigitte Cheuvart; Felix Espinoza; Paul Gillard; Bruce L Innis; Yolanda Cervantes; Alexandre C Linhares; Pío López; Mercedes Macías-Parra; Eduardo Ortega-Barría; Vesta Richardson; Doris Maribel Rivera-Medina; Luis Rivera; Belén Salinas; Noris Pavía-Ruz; Jorge Salmerón; Ricardo Rüttimann; Juan Carlos Tinoco; Pilar Rubio; Ernesto Nuñez; M Lourdes Guerrero; Juan Pablo Yarzábal; Silvia Damaso; Nadia Tornieporth; Xavier Sáez-Llorens; Rodrigo F Vergara; Timo Vesikari; Alain Bouckenooghe; Ralf Clemens; Béatrice De Vos; Miguel O'Ryan
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

2.  Burden of rotavirus disease in European Union countries.

Authors:  Montse Soriano-Gabarró; Jacek Mrukowicz; Timo Vesikari; Thomas Verstraeten
Journal:  Pediatr Infect Dis J       Date:  2006-01       Impact factor: 2.129

3.  Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study.

Authors:  K B Phua; F S Lim; Y L Lau; E A S Nelson; L M Huang; S H Quak; B W Lee; Y L Teoh; H Tang; I Boudville; L C Oostvogels; P V Suryakiran; I V Smolenov; H H Han; H L Bock
Journal:  Vaccine       Date:  2009-08-11       Impact factor: 3.641

4.  Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in austrian children.

Authors:  Maria Paulke-Korinek; Pamela Rendi-Wagner; Michael Kundi; Renate Kronik; Herwig Kollaritsch
Journal:  Pediatr Infect Dis J       Date:  2010-04       Impact factor: 2.129

5.  Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium.

Authors:  Mark Zeller; Mustafizur Rahman; Elisabeth Heylen; Sarah De Coster; Sofie De Vos; Ingrid Arijs; Luis Novo; Natasha Verstappen; Marc Van Ranst; Jelle Matthijnssens
Journal:  Vaccine       Date:  2010-09-17       Impact factor: 3.641

6.  Delayed onset and diminished magnitude of rotavirus activity--United States, November 2007-May 2008.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-06-27       Impact factor: 17.586

7.  Reduction in rotavirus after vaccine introduction--United States, 2000-2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-10-23       Impact factor: 17.586

8.  Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine.

Authors:  H Fred Clark; Diane Lawley; Laura A Mallette; Mark J DiNubile; Richard L Hodinka
Journal:  Clin Vaccine Immunol       Date:  2009-01-21

9.  Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5).

Authors:  Robbin Itzler; Gary Koch; David O Matson; Leif Gothefors; Pierre Van Damme; Mark J Dinubile; Penny M Heaton
Journal:  BMC Pediatr       Date:  2010-06-11       Impact factor: 2.125

10.  Global illness and deaths caused by rotavirus disease in children.

Authors:  Umesh D Parashar; Erik G Hummelman; Joseph S Bresee; Mark A Miller; Roger I Glass
Journal:  Emerg Infect Dis       Date:  2003-05       Impact factor: 6.883

View more
  7 in total

1.  Decline in rotavirus hospitalizations following the first three years of vaccination in Castile-La Mancha, Spain.

Authors:  Olga Redondo; Rosa Cano; Lorena Simón
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Risk of Intussusception After Rotavirus Vaccination.

Authors:  Judith Koch; Thomas Harder; Rüdiger von Kries; Ole Wichmann
Journal:  Dtsch Arztebl Int       Date:  2017-04-14       Impact factor: 5.594

3.  Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population.

Authors:  Sudeep Karve; Girishanthy Krishnarajah; Jennifer S Korsnes; Adrian Cassidy; Sean D Candrilli
Journal:  Hum Vaccin Immunother       Date:  2014-04-14       Impact factor: 3.452

4.  Impact of self-financed rotavirus vaccines on hospital stays and costs in Spain after a 3-year introductory period.

Authors:  O Redondo-González; J M Tenías-Burillo; J Ruiz-Gonzalo
Journal:  Epidemiol Infect       Date:  2017-04-03       Impact factor: 4.434

5.  Recommendation of rotavirus vaccination and herd effect: a budget impact analysis based on German health insurance data.

Authors:  Alexander Karmann; Andrea Jurack; Daniel Lukas
Journal:  Eur J Health Econ       Date:  2014-08-19

6.  Retrospective multicenter matched case-control study on the risk factors for intussusception in infants less than 1 year of age with a special focus on rotavirus vaccines - the German Intussusception Study.

Authors:  Doris Oberle; Marcus Hoffelner; Jutta Pavel; Dirk Mentzer; Immanuel Barth; Ursula Drechsel-Bäuerle; Brigitte Keller-Stanislawski
Journal:  Hum Vaccin Immunother       Date:  2020-04-09       Impact factor: 3.452

Review 7.  Established and new rotavirus vaccines: a comprehensive review for healthcare professionals.

Authors:  Volker Vetter; Robert C Gardner; Serge Debrus; Bernd Benninghoff; Priya Pereira
Journal:  Hum Vaccin Immunother       Date:  2021-02-19       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.